Management of Recurrent Epistaxis in Anticoagulated Patients

Immediate Management Approach

The American Academy of Otolaryngology-Head and Neck Surgery recommends continuing apixaban without interruption and aggressively pursuing first-line local control measures, such as nasal compression, topical vasoconstrictors, moisturizing agents, and cautery if needed, before considering any anticoagulation modification, as withholding anticoagulation increases thrombotic risk, which carries higher morbidity and mortality than the epistaxis itself 1, 2
Do not discontinue or reverse apixaban for recurrent epistaxis unless bleeding is life-threatening, as the American Academy of Otolaryngology-Head and Neck Surgery explicitly recommends initiating first-line treatments prior to transfusion, reversal of anticoagulation, or withdrawal of anticoagulation medications in the absence of life-threatening bleeding 1, 2, 3

Apply firm sustained compression to the lower third of the nose for 5-15 minutes with the patient seated and head tilted slightly forward, breathing through the mouth and spitting out blood rather than swallowing it, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 4
After compression, clean the nasal cavity of clots and apply topical vasoconstrictor, such as oxymetazoline or phenylephrine spray, which stops bleeding in 65-75% of cases, according to the American Academy of Otolaryngology-Head and Neck Surgery 4
If a specific bleeding site is identified on anterior rhinoscopy, perform nasal cautery using 75% silver nitrate, restricting cautery only to the active bleeding site, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 4
If bleeding persists, proceed to nasal packing, such as anterior or posterior packing, before considering any anticoagulation modification, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 1, 3

The cornerstone of preventing recurrent epistaxis in anticoagulated patients is aggressive nasal mucosal moisturization, according to the American Academy of Otolaryngology-Head and Neck Surgery 4
Apply petroleum jelly to the anterior nasal septum 1-3 times daily, particularly before bedtime, to maintain mucosal moisture, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 4
Use regular saline nasal sprays to maintain mucosal moisture throughout the day, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 4
Consider bedside humidification during sleep, especially in dry climates or during winter months, to maintain mucosal moisture, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 4

Only consider temporary interruption of apixaban if life-threatening bleeding is present, such as massive hemorrhage requiring transfusion, hemodynamic instability, or airway compromise, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 1, 3
Do not routinely use reversal agents, such as 4-factor PCC, for non-life-threatening epistaxis, as the risks of reversal, including thrombotic events and blood product exposure, outweigh benefits, according to the American Academy of Otolaryngology-Head and Neck Surgery 1, 3

Do not routinely discontinue anticoagulation to see if bleeding stops, as this practice is not evidence-based and significantly increases stroke risk, according to the American Academy of Otolaryngology-Head and Neck Surgery 1, 3
Do not administer fresh frozen plasma, platelet transfusions, or reversal agents for non-life-threatening epistaxis, as these expose patients to unnecessary risks without proven benefit, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 1, 3
Do not underestimate simple moisturization measures, as these are highly effective in preventing recurrence and should be the primary preventive strategy, according to the American Academy of Otolaryngology-Head and Neck Surgery 4
Do not perform bilateral cautery simultaneously, as this increases septal perforation risk, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 4

Document the outcome of intervention within 30 days to assess treatment effectiveness, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 4
Educate the patient about preventive measures, such as nasal moisturization, proper home treatment technique, and indications to seek emergency care, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 4
Assess for hereditary hemorrhagic telangiectasia if bilateral recurrent bleeding or visible nasal/oral telangiectasias are present, as this may require specialist referral and alternative management strategies, according to the American Academy of Otolaryngology-Head and Neck Surgery 4